Olopatadine Hydrochloride

CAS 113806-05-6 10 current records 4 historicalSmall Molecule

Who holds supplier records for Olopatadine Hydrochloride? 10 organisations hold a current record for Olopatadine Hydrochloride: an active US FDA Type II Drug Master File. A further 4 organisations have only historical (inactive) DMF filings. Recorded organisation countries for current records: India (6), Spain (1), Italy (1), Japan (1) and 1 other country (1).

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 13 Nov 2026. How we read these records

Cite as: PharmaTek, “Olopatadine Hydrochloride: DMF and CEP holder records”, record as of 13 Nov 2026, pharmatek.co.uk/directory/api/olopatadine-hydrochloride

Reading the evidence

  • 10 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • Most recorded organisations are in India

    6 of the 10 current records with a recorded country list India. Organisation country is not necessarily the manufacturing site.

  • 10 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

Current records (10)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Olopatadine Hydrochloride. Country is the organisation's recorded country, not necessarily the manufacturing site.

Need Olopatadine Hydrochloride sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Historical records (4)

Organisations whose Type II DMFs for Olopatadine Hydrochloride are no longer active. These show a past filing, not current supply.

Show all 4 historical records
  • Apotex Pharmachem India Pvt. Ltd.
    India · Inactive DMF 27171 · filed May 2013
  • CHUNGHWA CHEMICAL SYNTHESIS AND BIOTECH CO LTD
    Inactive DMF 22430 · filed Jan 2009
  • URQUIMA SA
    Inactive DMF 19417 · filed May 2006
  • Japan · Inactive DMF 11801 · filed Jan 1996

Other forms of this substance

A DMF or CEP is listed under the form it names. Salts, esters and hydrates of the same active substance have their own records:

Overview

Olopatadine hydrochloride is a selective histamine H1 receptor antagonist used to treat allergic conjunctivitis. It functions by inhibiting the release of histamine from mast cells and stabilizing them to prevent allergic reactions.

Chemical identity

IUPAC name
2-[(11Z)-11-[3-(dimethylamino)propylidene]-6H-benzo[c][1]benzoxepin-2-yl]acetic acid;hydrochloride
Canonical SMILES
CN(C)CC/C=C\1/C2=CC=CC=C2COC3=C1C=C(C=C3)CC(=O)O.Cl
InChIKey
HVRLZEKDTUEKQH-NOILCQHBSA-N
Synonyms
Patanol API, allelock, alo-4943a, alo4943a, kw-4679, kw4679, olopatadine (as hydrochloride), olopatadine hcl, pataday, patanase, patanol, pazeo

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Histamine-1 Receptor Antagonist; Histamine-1 Receptor Inhibitor; Mast Cell Stabilizer
Mechanism of action
Histamine H1 Receptor Antagonists
Physiologic effect
Decreased Histamine Release

Therapeutic areas

AllergyOphthalmology

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Olopatadine Hydrochloride?

10 organisations hold an active US FDA Type II Drug Master File or a CEP for Olopatadine Hydrochloride: CURIA SPAIN SAU (Spain), ALIVUS LIFE SCIENCES LTD (India), FDC Limited (India), FIS FABBRICA ITALIANA SINTETICI SPA (Italy), INDOCO REMEDIES LTD (India), KYOWA PHARMA CHEMICAL CO LTD (Japan), MSN Laboratories Private Limited (India) and PCAS (France), and 2 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Olopatadine Hydrochloride Drug Master Files are active?

CURIA SPAIN SAU (DMF 25044, 19526), ALIVUS LIFE SCIENCES LTD (DMF 31761), FDC Limited (DMF 29464), FIS FABBRICA ITALIANA SINTETICI SPA (DMF 23240, 26297), INDOCO REMEDIES LTD (DMF 24106), KYOWA PHARMA CHEMICAL CO LTD (DMF 28389), MSN Laboratories Private Limited (DMF 24624) and PCAS (DMF 23908) and 2 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

What do the historical Olopatadine Hydrochloride records mean?

4 organisations have only inactive Type II DMFs for Olopatadine Hydrochloride. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.

How do I qualify a Olopatadine Hydrochloride supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Olopatadine Hydrochloride?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.